NeuroPace, Inc. (NPCE)

5.10 -1.05 (-17.07%) At close: 04:00PM EDT

NeuroPace, Inc.

455 North Bernardo Avenue
Mountain View, CA 94043
United States
650 237 2700
https://www.neuropace.com

Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 166

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Michael L. Favet	Pres, CEO & Director	835.42k	N/A	1970
Ms. Irina Ridley	Gen. Counsel & Corp. Sec.	462.11k	N/A	1986
Dr. Martha J. Morrell	Chief Medical Officer	583.5k	N/A	1957
Ms. Rebecca L. Kuhn	CFO, VP of Fin. & Admin. and Assistant Sec.	N/A	N/A	1961
Ms. Chi Nguyen	VP of Marketing	N/A	N/A	1977
Mr. Mark S. Saxton	VP of Sales	N/A	N/A	1965
Ms. Irene Thomas	VP of HR	N/A	N/A	1969
Mr. Andre G. Marquette	Chief Commercial Officer	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Corporate Governance

NeuroPace, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.